336 related articles for article (PubMed ID: 17882194)
1. Biotechs go generic: the same but different.
Ledford H
Nature; 2007 Sep; 449(7160):274-6. PubMed ID: 17882194
[No Abstract] [Full Text] [Related]
2. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
3. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 1.
Kuhrt K; Chace-Ortiz M
IDrugs; 2009 Dec; 12(12):760-4. PubMed ID: 19943217
[TBL] [Abstract][Full Text] [Related]
4. Reinventing an industry.
Mandavilli A
Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
[No Abstract] [Full Text] [Related]
5. Congress works to permit 'biosimilar' drugs very soon.
Carroll J
Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
[No Abstract] [Full Text] [Related]
6. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
7. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
8. Market watch: Sales of biologics to show robust growth through to 2013.
Goodman M
Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035
[No Abstract] [Full Text] [Related]
9. Equivocal role of micelles in Eprex adverse events.
Smiell JM
Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595347
[No Abstract] [Full Text] [Related]
10. Equivocal role of micelles in Eprex adverse events.
Schellekens H; Crommelin DJ
Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595346
[No Abstract] [Full Text] [Related]
11. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
12. Lessons from Eprex for biogeneric firms.
Louët S
Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
[No Abstract] [Full Text] [Related]
13. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
14. Betting on biogenerics.
Dove A
Nat Biotechnol; 2001 Feb; 19(2):117-20. PubMed ID: 11175723
[No Abstract] [Full Text] [Related]
15. How Indian biotech is driving innovation.
Nogrady B
Nature; 2018 Dec; 564(7735):S53-S55. PubMed ID: 30542184
[No Abstract] [Full Text] [Related]
16. US biotech prepares to fight generic biologics.
Reid B
Nat Biotechnol; 2002 Apr; 20(4):322. PubMed ID: 11923820
[No Abstract] [Full Text] [Related]
17. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 2.
Kuhrt K
IDrugs; 2009 Dec; 12(12):765-9. PubMed ID: 19943218
[TBL] [Abstract][Full Text] [Related]
18. 'Follow-on biologics': ensuring continued innovation in the biotechnology industry.
Manheim BS; Granahan P; Dow KJ
Health Aff (Millwood); 2006; 25(2):394-404. PubMed ID: 16610097
[TBL] [Abstract][Full Text] [Related]
19. Handle with care.
Macilwain C
Nature; 2006 Apr; 440(7087):990-1. PubMed ID: 16625170
[No Abstract] [Full Text] [Related]
20. Trade deal to curb generic-drug use.
Maxmen A
Nature; 2012 Sep; 489(7414):16-7. PubMed ID: 22962700
[No Abstract] [Full Text] [Related]
[Next] [New Search]
